Journal: American Journal of Physiology - Lung Cellular and Molecular Physiology

Article Title: A mouse model of progressive lung fibrosis with cutaneous involvement induced by a combination of oropharyngeal and osmotic minipump bleomycin delivery

doi: 10.1152/ajplung.00408.2023

Figure Lengend Snippet: Schematic representation of the experimental setting and body weight variation over time. A : dose-finding study: 25 eight-wk-old female C57BL/6 mice were treated via OA with saline or bleomycin (BLM; 10 or 15 µg) at day 0 ; five animals were used for the saline and for each of the BLM OA+Pump groups. At day 7 , osmotic mini-pumps filled with either saline or BLM (80 or 100 mg/kg) were implanted subcutaneously. At day 14 , pumps were removed. At day 42 , animals were subjected to noninvasive in vivo micro-CT imaging, BALF cells count, lung, and skin histology. B : time-course analysis and NTD treatment pilot study: 15 eight-weeks-old female C57BL/6 mice were treated via OA with saline or BLM (15 µg) at day 0 , followed by micro-CT imaging at day 7 . Osmotic mini-pumps filled with either saline or BLM (100 mg/kg) were then implanted subcutaneously and removed at day 14 as above. At days 28 , 35 , and 42 mice were examined longitudinally by noninvasive, in vivo micro-CT imaging. Subsets of 5 mice/group were euthanized at each time-point for BALF cells counting, plus lung and skin histology. An additional subset of five mice subjected to the BLM OA+Pump (15 + 100) mixed administration regimen were treated with NTD (60 mg/kg/day orally) from day 28 to day 42 and imaged by micro-CT only at day 42 before euthanasia and ex vivo analysis. C : body weight variation in the saline and BLM OA+Pump (10 + 0, 10 + 80, 10 + 100, and 15 + 100) groups, given as mean ± SD for each time-point and for the various groups, expressed as percent variation compared with the body weight determined in the saline controls at day 0 . Statistical significance was evaluated by two-way ANOVA with Tukey’s test for multiple comparisons; ** P < 0.01 vs. saline. D : body weight variation in the saline, BLM OA+Pump (15 + 100), and BLM OA+Pump (15 + 100)+NTD treatment groups, expressed and statistically evaluated as specified in the legend to B . ** P < 0.01 vs. saline. BALF, bronchoalveolar lavage fluid; micro-CT, micro-computed tomography; NTD, Nintedanib; OA, oropharyngeal aspiration.

Article Snippet: A subgroup of five BLM-treated mice received a daily oral gavage of Nintedanib (NTD, 60 mg/kg/day in a volume of 10 mL/kg, Carbosynth Limited, Compton, UK) dissolved in a saline solution of Tween 80 (0.05% vol/vol) from day 28 to day 42 .

Techniques: Saline, In Vivo, Micro-CT, Imaging, Ex Vivo

Journal: iScience

Article Title: Multiphase micro-computed tomography reconstructions provide dynamic respiratory function in a mouse lung fibrosis model

doi: 10.1016/j.isci.2024.109262

Figure Lengend Snippet:

Article Snippet: Nintedanib Ethanesulfonate Salt , Carbosynth Limited, Compton, UK , FD71497.

Techniques: Recombinant, Software

Journal: Theranostics

Article Title: Blockade of phosphotyrosine pathways suggesting SH2 superbinder as a novel therapy for pulmonary fibrosis

doi: 10.7150/thno.72269

Figure Lengend Snippet: SH2 superbinder had better anti-fibrotic effect than nintedanib. After BLM (2 U/kg) treatment, PBS, GST-SH2 TrM (5 mg/kg) and nintedanib (20 mg/kg) were intratracheally injected at day 14 and 17, all mice were sacrificed at day 21. A , Schematic showing progression of GST-SH2 TrM and nintedanib in this model. B , Representative microCT reconstitution images of 3D and cross sections of lungs. Arrows showed the fibrosis foci which resulted in serious parenchymal destruction and volume reduction of lungs. C , Lung volume calculation by CTvox after 3D reconstitution of lungs (n = 6). ** P < 0.01, *** P < 0.001. D , Lung weights shown as bar charts (n = 6). * P < 0.05, *** P < 0.001. E , Lung hydroxyproline content in different groups (n = 6). * P < 0.05, ** P < 0.01, *** P < 0.001. F , Soluble collagen content in different groups (n = 6). ** P < 0.01, *** P < 0.001. G , Masson's trichrome staining in different groups. Images showing the panoramic and partial view of mice lung. Arrows pointed to the collagen deposition. H-I , Collagen percentage ( H ) and fibrosis score ( I ) of lungs after PBS, GST-SH2 WT, GST-SH2 TrM or SH2 TrM treatment (n = 6). * P < 0.05, ** P < 0.01, *** P < 0.001. J-K , Western blot of FN, COL1A1 and α-SMA in lung tissues from different groups (n = 6). * P < 0.05, ** P < 0.01, *** P < 0.001. L , Expression change of fibrosis associated genes after PBS, nintedanib or GST-SH2 TrM treatment (n = 6). M-O , Lung compliance ( M ), elastance ( N ) and resistance ( O ) were measured using Forced Manoeuvres System (n = 6). * P < 0.05, ** P < 0.01, *** P < 0.001. P-S , TLC ( P ), FRC ( Q ), RV ( R ) and PEF ( S ) were compared between nintedanib or GST-SH2 TrM treated mice (n = 6). * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: Bleomycin, nintedanib and PHPS1 were purchased from Targetmol (Boston, MA, USA).

Techniques: Injection, Staining, Western Blot, Expressing

Journal: Cell death & disease

Article Title: FOXA1 prevents nutrients deprivation induced autophagic cell death through inducing loss of imprinting of IGF2 in lung adenocarcinoma.

doi: 10.1038/s41419-022-05150-8

Figure Lengend Snippet: Fig. 7 FOXA1 expression reduced the efficacy of nintedanib against xenograft tumors derived from A549 cells. A Growth curve of xenograft tumors in nude mice. Mean ± SD, n = 10. B Macro view of xenograft tumors. C Weights of xenograft tumors as measured at the endpoint of the experiment. Mean ± SD, n = 10. D H&E staining and immunohistochemistry staining of xenograft tumors. Ni nintedanib (100 mg/kg). li linsitinib (25 mg/kg). ra rapamycin (4 mg/kg).

Article Snippet: The EGFR-TKI Erlotinib (cat. no. OSI-774), Gefitinib (cat. no. ZD1839), the IGF1R inhibitor linsitinib (cat. no. S1091), rapamycin (cat. no. S1039), Fer-1 (cat. no. S7243), MG132 (cat. no. S2619), and nintedanib ethanesulfonate salt (cat. no. S5234) were purchased from Selleckchem (Shanghai, China).

Techniques: Expressing, Derivative Assay, Staining, Immunohistochemistry

Journal: Scientific Reports

Article Title: Integrated computational and experimental pipeline for quantifying local cell–matrix interactions

doi: 10.1038/s41598-021-95935-2

Figure Lengend Snippet: Analyses of TGF-β and Nintedanib-treated spheroids. ( A ) Day 5 NHLF29800 and IPF29548 spheroids treated with Nintedanib, TGF-β, TGF-β + Nintedanib. Scale bar, 100 μm. ( B ) 2D collagen density fold change at hour 6 normalized by the TGF-β only condition for NHLF29800 and IPF29548 spheroids (each data point is a spheroid). ( C ) 3D collagen density fold change at hour 6 normalized by the TGF-β only condition for NHLF29800 and IPF29548 spheroids (each data point is a spheroid). ( D ) Day 7 hole size normalized by the TGF-β only condition for NHLF29800 and IPF29548 spheroids in different conditions (each data point is a spheroid). T stands for TGF-β. N stands for Nintedanib.

Article Snippet: The treatment and their concentrations are 10 ng/mL TGF-β (PeproTech, cat.# 100-21), 5 μM Nintedanib (Santa Cruz, cat.# 656247-18-6), 20 μM GM6001 (abcam, cat.# ab120845), or 100 μM SMIFH2 (abcam, cat.# ab218296).

Techniques: